Fulphila: The First FDA-Approved Biosimilar for Neulasta Mar 19, 2019Mar 20, 2019 Brand: Fulphila (pegfilgrastim-jmdb), Injection Parent Company: Mylan Drug Type: Prescription Drug Category: Oncology Campaign: now-approved Targeting: HCPs Patient Website: HCP Website: http://www.fulphila.com/ Home Efficacy Patient Support Sign Up Home (Mobile) Mobile Nav